Streetbeat News

Price Targets

VEEV

20 analysts have recently reviewed Veeva Systems (NYSE:VEEV), showing a mix of bullish and bearish sentiments. The average 12-month price target is now $243.5, up from $219.00, indicating an 11.19% increase. Analysts' ratings range from 'Buy' to 'Underweight', with several maintaining their previous ratings and others raising their price targets. Veeva Systems, a leading provider of cloud-based solutions for the life sciences industry, has shown strong financial performance with a revenue growth rate of 11.93%, a net margin of 23.37%, and an ROE of 3.27%.

Portfolio Pulse from Benzinga Insights

April 02, 2024 | 1:00 pm

DIS

Needham analyst Laura Martin maintains a Buy rating on Walt Disney (NYSE:DIS) with a maintained price target of $145.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:58 pm

EL

Estee Lauder's stock price increased following an upgrade by Citigroup from Neutral to Buy, with a raised price target from $160 to $175.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:57 pm

ANVS

HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Annovis Bio (ANVS) with a maintained price target of $30.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:56 pm

REXR

Mizuho analyst Vikram Malhotra maintains a Neutral rating on Rexford Industrial Realty (REXR) with a $52 price target.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:56 pm

EQ

HC Wainwright & Co. analyst Raghuram Selvaraju maintains a Buy rating on Equillium (NASDAQ:EQ) and raises the price target from $4 to $5.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:55 pm

PLD

Mizuho analyst Vikram Malhotra maintains a Neutral rating on Prologis (NYSE:PLD) with a $130 price target.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:54 pm

ENTX

HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Entera Bio (NASDAQ:ENTX) with a price target of $10.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:54 pm

AXSM

HC Wainwright & Co. analyst Raghuram Selvaraju has reaffirmed a Buy rating on Axsome Therapeutics (NASDAQ:AXSM) with a maintained price target of $190.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:53 pm

FR

Mizuho analyst Vikram Malhorta maintains a Buy rating on First Industrial Realty (NYSE:FR) with a $58 price target, indicating a positive outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:53 pm